Rybix ODT Side Effects
Generic name: tramadol
Note: This document contains side effect information about tramadol. Some of the dosage forms listed on this page may not apply to the brand name Rybix ODT.
Some side effects of Rybix ODT may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to tramadol: oral capsule extended release, oral tablet, oral tablet disintegrating, oral tablet extended release
Get emergency medical help if you have any of these signs of an allergic reaction while taking tramadol (the active ingredient contained in Rybix ODT) hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using tramadol and call your doctor at once if you have any of these serious side effects:
-
agitation, hallucinations, fever, fast heart rate, overactive reflexes, nausea, vomiting, diarrhea, loss of coordination, fainting;
-
seizure (convulsions);
-
a red, blistering, peeling skin rash; or
-
shallow breathing, weak pulse.
Less serious side effects of tramadol may include:
-
dizziness, spinning sensation;
-
constipation, upset stomach;
-
headache;
-
drowsiness; or
-
feeling nervous or anxious.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to tramadol: oral capsule extended release, oral tablet, oral tablet disintegrating, oral tablet extended release
Gastrointestinal
Gastrointestinal side effects are common. Nausea and constipation occur within the first 90 days of therapy in 40% and 46% of treated patients, respectively. Vomiting, diarrhea, dyspepsia, anorexia, flatulence, abdominal pain, and dry mouth have also been reported.
Nervous system
Seizures have been reported in patients receiving the normal recommended dose. The risk for seizures is increased with doses above the recommended range.
Nervous system side effects occur frequently. Dizziness, headache, and somnolence have been reported in more than 25% of treated patients during the first three months of therapy. CNS stimulation, including nervousness, anxiety, tremor, agitation, euphoria, emotional lability and hallucinations, has also been reported. Confusion, sleep disorders, and coordination disturbances have been reported in less than 5% of patients. Seizures have been reported in over 200 cases. Cases of long-lasting delirium have been reported in two elderly patients. A case of serotonin syndrome triggered by tramadol has also been reported.
Dermatologic
Dermatologic side effects including pruritus (11%) have been reported. Rash and urticaria have occurred rarely.
Genitourinary
Genitourinary side effects including urinary retention and urinary frequency have been reported in less than 5% of treated patients.
Cardiovascular
Cardiovascular side effects including tachycardia and orthostatic hypotension have been reported rarely.
Hypersensitivity
The use of tramadol (the active ingredient contained in Rybix ODT) is contraindicated for patients with a history of allergy to any opioid.
Hypersensitivity side effects including anaphylactoid reactions have been reported after first doses of tramadol as well as in patients with a documented history of codeine allergy. Angioedema has been reported rarely.
Other
Other side effects including withdrawal symptoms and, rarely, auditory hallucinations have been reported. A case of vocal cord closure has also been reported.
Metabolic
Metabolic side effects including hyponatremia have been reported.
More Rybix ODT resources
- Rybix ODT Prescribing Information (FDA)
- Rybix ODT orally disintegrating tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Rybix ODT Advanced Consumer (Micromedex) - Includes Dosage Information
- ConZip Prescribing Information (FDA)
- ConZip extended-release capsules MedFacts Consumer Leaflet (Wolters Kluwer)
- Ryzolt Consumer Overview
- Ryzolt Prescribing Information (FDA)
- Ryzolt extended-release tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Tramadol Hydrochloride Monograph (AHFS DI)
- Ultram Prescribing Information (FDA)
- Ultram Consumer Overview
- Ultram ER Prescribing Information (FDA)
- tramadol MedFacts Consumer Leaflet (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.


